

Supplementary Table 1. Hallucination and orthostatic hypotension according to use of antiparkinson medication

Variables		Hallucination		χ^2 (p)	Orthostatic hypotension		χ^2 (p)
		n (%)			n (%)		
		Yes	No		Yes	No	
COMT inhibitor	Yes	8 (61.5)	74 (46.3)	1.13 (0.389)	41 (48.2)	41 (46.6)	0.05 (0.879)
	No	5 (38.5)	86 (53.7)		44 (51.8)	47 (53.4)	
Dopamine agonist	Yes	10 (76.9)	114 (71.3)	0.19 (> 0.999)	71 (83.5)	35 (39.8)	11.56 (0.001)
	No	3 (23.1)	46 (28.7)		14 (16.5)	53 (60.2)	
Amantadine	Yes	5 (38.5)	80 (50.0)	0.64 (0.567)	51 (60.0)	34 (38.6)	7.90 (0.006)
	No	8 (61.5)	80 (50.0)		34 (40.0)	54 (61.4)	
MAO-B inhibitor- rasagiline	Yes	3 (23.1)	35 (21.9)	0.01 (> 0.999)	24 (28.2)	14 (15.9)	3.83 (0.066)
	No	10 (76.9)	125 (78.1)		61 (71.8)	74 (84.1)	
Anticholinergics	Yes	0 (0.0)	3 (1.9)	0.25 (> 0.999)	2 (2.4)	1 (1.1)	0.38 (0.616)
	No	13 (100.0)	157 (98.1)		83 (97.6)	87 (98.9)	
SSRI	Yes	0 (0.0)	6 (3.8)	0.50 (> 0.999)	4 (4.7)	2 (2.3)	0.77 (0.438)
	No	13 (100.0)	154 (96.2)		81 (95.3)	86 (97.7)	
Quetiapine	Yes	7 (53.8)	7 (4.4)	39.56 (< 0.001)	6 (7.1)	8 (9.1)	0.24 (0.782)
	No	6 (46.2)	153 (95.6)		79 (92.9)	80 (90.9)	

COMT inhibitor: catechol-O-methyltransferase inhibitor, MAO-B inhibitor: monoamine oxidase-B inhibitor, SSRI: selective serotonin reuptake inhibitor.